|
| 1） |
Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61（5）:1285-90. |
| 2） |
Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer（an EORTC study）:a phase III randomized trial. Lancet. 2002 Jul 13;360（9327）:103-6. |
| 3） |
Hanks GE, Pajak TF, Porter A, et al. Phase III Trial of Long-Term Adjuvant Androgen Deprivation after Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate:The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972-8. |
| 4） |
Roach M 3rd, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormonal therapy:a meta-analysis of the RTOG prostate cancer trials. Int J Radiat Oncol Phys. 2000;47:617-27. |
| 5） |
D'Amico AV, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer:a randomized controlled trial. JAMA. 2004 292:821-7. |
| 6） |
Pilepich MV, et al. Phase III radiation therapy oncology group（RTOG）trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-52. |
| 7） |
Laverdière J, Nabid A, Bedoya LDD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004;171:1137-40. |
| 8） |
Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Phys. 2004;60:15-23. |
| 9） |
Roach M 3rd, DeSilvio M, Lawton C, et al. Radiation Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression:Radiation Oncology Group 9413. J Clin Oncol. 2003;21:1904-11. |
新検索ページはこちら
ログイン
お問い合わせ
書誌情報
